Vanguard Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$117M Buy
5,790,801
+27,051
+0.5% +$726K ﹤0.01% 1435
2026
Q2
$146M Buy
5,763,750
+102,350
+2% +$2.25M ﹤0.01% 1335
2026
Q1
$126M Buy
+5,661,400
New +$135M ﹤0.01% 1344

Other funds holding ACAD

Vanguard Capital Management's ACAD Position: Q3 2026 in Review

Vanguard Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 0.47% in Q3 2026, buying an estimated $726K and bringing the position to 5,790,801 shares worth $117M. The position accounts for ﹤0.01% of the portfolio, ranked #1435.

Vanguard Capital Management first reported a position in ACAD in Q1 2026 and has held it in 3 quarters since. The position peaked at $146M in Q2 2026. 350 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Vanguard Capital Management held 5,790,801 shares of Acadia Pharmaceuticals worth $117M as of Q3 2026.
  • Vanguard Capital Management bought 27,051 Acadia Pharmaceuticals shares in Q3 2026, an estimated $726K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1435 holding.
  • Vanguard Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Acadia Pharmaceuticals position peaked at $146M in Q2 2026.
  • 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.